Citigroup, Leerink Swann are bookrunners; Piper Jaffray, JMP assist
By Devika Patel
Knoxville, Tenn., Sept. 19 - Acceleron Pharma Inc. said it priced its $83.7 million initial public offering of stock with a $12.56 million greenshoe. The deal was announced on Aug. 7.
The company will sell 5.58 million common shares at $15.00 per share.
Citigroup and Leerink Swann are the joint bookrunning managers.
Proceeds will be used for clinical development of dalantercept, to advance and expand preclinical research and for general and administrative expenses, potential future development programs, early-stage research and development, capital expenditures, working capital and other general corporate purposes.
Celgene Corp. will invest $10 million in a separate private placement of 666,667 common shares at $15.00 per share.
Based in Cambridge, Mass., Acceleron is a clinical stage biopharmaceutical company. The company intends to list its common stock on the Nasdaq under the symbol "XLRN."
| Issuer: | Acceleron Pharma Inc.
|
| Issue: | Common stock
|
| Amount: | $83.7 million
|
| Greenshoe: | $12,555,000
|
| Shares: | 5.58 million
|
| Price: | $15.00
|
| Warrants: | No
|
| Bookrunners: | Citigroup and Leerink Swann
|
| Lead manager: | Piper Jaffray & Co.
|
| Co-manager: | JMP Securities LLC
|
| Announcement date: | Aug. 7
|
| Pricing date: | Sept. 19
|
| Stock exchange: | Nasdaq: XLRN
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
